FierceBiotech

Gilead tries new triple-target T-cell engagers in $1.5B-plus Merus collab

Bispecific T-cell engagers are just now stepping into the oncology spotlight, but that’s not stopping one pharma company from investigating the next frontier of the modality. Gilead and Merus have ...
FierceBiotech

Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med

Gilead Sciences is bolstering its liver disease portfolio with the $4.3 billion acquisition of CymaBay Therapeutics, specifically for the primary biliary cholangitis (PBC) med seladelpar. The deal ...
Business Wire

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral ...

FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new results from ...
Forbes

Should You Buy Gilead Stock At $110?

Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...
Business Wire

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada ® for HIV Prevention

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the ...